Press Releases Archives | Page 6 of 6

Research from CureMatch Co-Founder Selected by ASCO as Major Achievement in Clinical Cancer Research and Care

Matching Score Next-Generation Sequencing Oncology

Next-generation sequencing study validates a core principle behind the CureMatch technology SAN DIEGO, CA – February 16, 2017 – CureMatch, the developer of a decision support platform for combination therapy in cancer, today announced that research from their co-founder and Chief Medical Advisor, Dr. Razelle Kurzrock, was selected by the American Society of Clinical Oncology […]

CureMatch Announces Publication in OncoImmunology of Data Unveiling a Specific Mutagenesis Process Linked to the Response to Immunotherapy in Cancer

Cancer Immunotherapy PD-1

OncoImmunology Publication Validates Need to Determine Specific Subset of Mutations that Elicit Cancer Therapy Response SAN DIEGO, CA – February 7, 2017 – CureMatch, the developer of a Decision Support System for combination therapy in cancer, today revealed in the peer-reviewed journal OncoImmunology the description of a specific mechanism that can potentially be used for selecting […]

CureMatch Selected As Finalist At BIOCOM DeviceFest Pitch Competition

Pitch Competition Startup

CureMatch has been selected to compete in the “Five in 5 in the Hot Seat” Pitch Competition at BIOCOM DeviceFest. About CureMatch CureMatch™, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized […]

CureMatch Recognized As 2016 Cool Company By San Diego Venture Group

Innovation Startup Venture Funding

CureMatch was selected by the San Diego Venture Group as one of the 2016 Cool Companies! SDVG accepted 31 out of 140 applicants. The Cool Companies are companies that most prepared to raise venture funding. CureMatch noticed for a decision support system which helps oncologists select an optimal drug combination based upon the genetics of each patient’s tumor. SAN DIEGO’S […]

CureMatch Selected To Join JLABS Incubator

CureMatch has been selected to partner with JLABS-San Diego, a Johnson & Johnson Innovation Center. The JLABS incubator is located on the Torrey Pines mesa near La Jolla. JLABS provides access to state-of-the-art equipment, facilities and operations management.

CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer
Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...
Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials
Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...
Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy
Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....
Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov™
PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a...
How Precision Medicine Can Help You
Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient...
64 FDA-Approved Drugs Identified as Potential Treatments for COVID-19
Scientists from CureMatch and UCSD use pharmacophore-based drug design and a molecular docking technique to...
The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments
Oncology is currently the largest area of clinical health expenditures for prescription drugs in the...

Press Releases

Research from CureMatch Co-Founder Selected by ASCO as Major Achievement in Clinical Cancer Research and Care

CureMatch Announces Publication in OncoImmunology of Data Unveiling a Specific Mutagenesis Process Linked to the Response to Immunotherapy in Cancer

CureMatch Selected As Finalist At BIOCOM DeviceFest Pitch Competition

CureMatch Recognized As 2016 Cool Company By San Diego Venture Group

CureMatch Selected To Join JLABS Incubator

We’d like to send you a CureMatch Sample Analysis

Sample Analysis Download Form

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data